Feeder free expansion and closed wash and concentration of a clinically relevant number of human NK cells

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

As part of the innate immune response, Natural Killer (NK) cells respond to anything they perceive as “non-self”, including malignant cells, making them a promising effector cell for adoptive immunotherapy of cancers. Unlike T-cells, NK cells provide an anticancer response in an antigen independent manner, allowing NK cells to be a potential “off the shelf” allogeneic therapeutic product. Thus, they have the potential to be safer, less expensive, and more effective than current engineered T-cell therapies. One of the key challenges faced by the cell and gene therapy industry is the ability to expand and process NK cells using regulation-compliant reagents and closed manufacturing systems. In this presentation, we will discuss how CTS™ NK-Xpander™ Medium and the CTS™ Rotea™ Counterflow Centrifugation System increase the ability to generate and process large numbers of functionally viable human NK cells, filling a need for translational researchers to bring NK adoptive cell therapies to the clinic.

CTS™ NK-Xpander™ Medium, a new NK cell culture medium developed to support feeder-free human NK cell expansion in vitro, expands functional primary human NK cells to clinically relevant levels in two to three weeks. NK cells cultured with CTS NK-Xpander Medium in a G-rex®, Xuri™ Cellbag or HyPerforma™ Bioreactor yields up to 6 billion functional NK cells within 3 weeks.

The Gibco™ CTS™ Rotea™ Counterflow Centrifugation System is a closed cell processing system developed for small-batch cell therapy manufacturing. Using the CTS™ Rotea™ system, Leukopaks were processed and human NK cells enriched by negative selection. Post expansion, the NK cells were loaded into the CTS™ Rotea™ system to form a stabilized bed for subsequent washing in CTS™ DPBS. Recovery was ~90% with high viability and maintenance of cellular phenotype and function.

• Discuss the potential of NK cells in a clinical setting
• Learn about the ability to expand enriched human NK cells in a variety of scale up technologies in a feeder free system
• Understand how the Rotea system can wash and concentrate both Leukopaks and expanded human NK cells

Erica Heipertz PhD

Staff Scientist, Thermo Fisher Scientific

Erica Heipertz, PhD is a Staff Scientist at Thermo Fisher Scientific where she focuses on the development of new products for cell and gene therapy applications. Dr. Heipertz received her PhD in Microbiology and Immunology from Penn State University College of Medicine and performed her postdoctoral work at the National Institutes of Health and Texas Tech University Health Sciences Center.

Watch now

SPEAKERS

Erica Heipertz PhD

Staff Scientist, Thermo Fisher Scientific

You might also like

Creating a closed-process, semi-automated workflow for human MSC expansion, harvest, and final fill

Julien Muzard, Donnie Beers

30 May

Watch

Clinical-scale non-viral gene edited CAR-NK cells for cell therapy

Krishanu Saha, Namritha Ravinder

18 September

Watch

Mastering allogeneic NK cell therapies: flexibility, robustness, and speed to clinic

Tey Irrazabal

1 February

Watch

Large-scale manufacturing of allogeneic stem cell-derived NK cell therapies

Monica Raimo, Jan Spanholtz

6 August

Watch

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya

1 August

Watch